Advances in Immunotherapy of Malignant Pleural Mesothelioma

Abstract

Dongying Liao,1,2 Yongchao Yu,1,2 Qingyun Mei,1,2 Ziwei Wang,1,2 Xiaojiang Li,1,2 Yingjie Jia,1,2 Fanming Kong1,2 1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, Tianjin, 300193, People’s Republic of China; 2National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Nankai District, Tianjin, 300193, People’s Republic of ChinaCorrespondence: Fanming KongDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Anshanxi Road, Nankai District, Tianjin, 300193, People’s Republic of ChinaTel + 86 136 52123653Email [email protected]: Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.Keywords: malignant pleural mesothelioma, immunotherapy, progression, ipilimumab, nivolumab

Keywords

• malignant pleural mesothelioma
• immunotherapy
• progression
• ipilimumab
• nivolumab